Vitalhub (VHI) Stock Price, News & Analysis

Company Overview

Vitalhub Corp is Canada-based firm that develops technology solutions for health and human services providers in the mental health (child through adult), long term care, community health service, home health, social service, and acute care sectors. Its technologies include blockchain, mobile, patient flow, web-based assessment, and electronic health record solutions.

Key Stats

• Today's Range: C$7.36 to C$7.44
• 50-Day Range: C$6.80 to C$8.30
• 52-Week Range: C$6.62 to C$14.64
• Volume: 43,423 shs
• Average Volume: 367,972 shs
• Market Capitalization: C$468.12 million
• P/E Ratio: 61.67
• Dividend Yield: N/A
• Price Target: C$13.14
• Consensus Rating: Buy

Vitalhub Stock Analysis - MarketRank™

Vitalhub scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Buy

Consensus Rating

Vitalhub has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Vitalhub has a consensus price target of C$13.14, representing about 77.6% upside from its current price of C$7.40.

Amount of Analyst Coverage

Vitalhub has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vitalhub is 61.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vitalhub is 61.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.99.

Price to Earnings Growth Ratio

Vitalhub has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Vitalhub has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VHI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vitalhub does not currently pay a dividend.

Dividend Growth

Vitalhub does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Vitalhub has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vitalhub this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for VHI on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vitalhub insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$71,700.00 in company stock.

Percentage Held by Insiders

18.57% of the stock of Vitalhub is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

26.64% of the stock of Vitalhub is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/05/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: Chemicals
• Current Symbol: TSE:VHI
• CIK: N/A
• Web: vitalhub.com
• Phone: 416-699-0123
• Fax: N/A
• Employees: 2,250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vitalhub: C$13.14
• High Price Target: C$16.00
• Low Price Target: C$11.00
• Potential Upside/Downside: +77.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.12
• Trailing P/E Ratio: 61.67
• Forward P/E Ratio: 32.22
• P/E Growth: 1.18
• Net Income: C$3.35 million
• Net Margins: 6.13%
• Pretax Margin: N/A
• Return on Equity: 2.98%
• Return on Assets: 3.81%

Debt

• Debt-to-Equity Ratio: 0.97
• Current Ratio: 2.26
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$119.20 million
• Price / Sales: 3.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$4.26 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 63,260,000
• Free Float: N/A
• Market Cap: C$468.12 million
• Optionable: Not Optionable
• Beta: 0.91